MedPage Today2h
Florida's Canadian Drug Import Plan Goes Nowhere After FDA Approval
Colorado and Florida are among at least nine states that have passed laws allowing for Canadian drug importation. Colorado's ...
Is Your Mind Ready to Consider Investing in Psychedelics Stocks?
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest ...
The American Journal of Managed Care1d
Advent of Ponatinib for Ph+ ALL Expected to Influence New Guidelines
With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia ...
PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts
PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...
Applied Therapeutics: FDA Denial Of Govorestat NDA As Problematic As It Was Unexpected
Applied Therapeutics faces challenges after FDA rejection, but future opportunities exist. Learn why APLT stock could recover ...
Richmond2d
Virginia: Work group says hold off on drug import program
Virginia should see if other states’ plans to import lower-cost medications from Canada work before asking for federal ...
A Short Lesson in Drug Competition
See the new treatment that will break a Pfizer monopoly on a drug for heart disease.
US FDA declines to approve Applied Therapeutics' genetic disease drug
Applied Therapeutics said on Wednesday that the U.S. FDA declined to approve its drug to treat galactosemia, a rare genetic ...
JD Supra3d
FDA Provides Perspective on Goals and Challenges for Regulation of Artificial Intelligence in Medical Devices, Drug Design, and Clinical Research
A recent article authored by Haider J. Warraich, MD; Troy Tazbaz; and Robert M. Califf, MD in the Journal of the American ...
FiercePharma3d
FDA oncology advisory committee to weigh Exelixis' Cabometyx in neuroendocrine tumors
Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will ...
BioSpace3d
The Biggest Pharma Share Moves of the Year So Far
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
FierceBiotech3d
Outlook's stock plummets after eye drug fails to match Lucentis, but biotech still plans FDA filing
Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...